Extramural Funding Opportunities

NOSI, K12, F99/K00, P20, and RC2 AWARDS

Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program. Posted 11/28/2022. Expires 10/20/2023.

The Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Transition Award (F99/K00) is designed to help recruit truly exceptional graduate students, who are currently NOT involved in K, U, or H research and provide them a stable transition into a postdoctoral research experience focused on KUH research. This is an exceptional opportunity to recruit graduate students with diverse perspectives from fields including, but not limited to, engineering, statistics, data science, imaging, biochemistry, neuroscience and genetics. Prospective mentors and applicants are strongly encouraged to contact the NIDDK Program Official, Christine Maric-Bilkan (christine.maric-bilkan@nih.gov) to discuss eligibility and program goals. Posted 3/17/2022. Expires 4/2/2025.

High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK.  The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK. Posted 11/30/2021.  LOI due six weeks prior to application due date. Expires 10/31/24.

R21 AWARDS

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Posted 8/20/2021. Standard due dates. Expires 9/8/2024.

Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) This FOA is intended to support tool or technology development projects that will open new areas of science or translational research. The projects supported by this FOA must involve development activities, which could include prototyping of a new tool or significant improvement, adaptation, or optimization of an existing technology for the unique anatomy or physiology of KUH systems. In addition to development activities, projects may also include proof-of-concept studies and refinement of technical specifications for subsequent deployment of the technology in laboratory or clinical settings. Independent proof-of-concept studies or hypothesis-driven research, without any technological development activities, will not be supported by this FOA. The tools and technologies developed under this FOA should be truly innovative and break new ground or extend previous discoveries toward new directions or applications. Applications to this FOA should include projects distinct from those that can be supported through the traditional R01 grant mechanism. This FOA is not intended to support “mini-R01s” with a traditional hypothesis-driven research plan. Furthermore, long-term projects, or projects designed to increase knowledge in a well-established area, are not appropriate for this FOA. Strong applications will develop new tools or technologies in kidney, urology or hematology with broad utility beyond the applicant’s own laboratory and ideally push the entire field forward. Posted 4/11/2023. Expires 1/8/2025.

RO1 AWARDS

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01—Clinical Trial Required) This NIDDK Funding Opportunity Announcement will support pilot and feasibility trials to test interventions that involve screening for and addressing adverse social determinants of health (SDoH), also called social risks, during a health care visit. Patients’ endorsed social needs could be addressed by appropriately referring/navigating patients or caregivers to resources that address these issues at social service organizations located externally or co-located in the healthcare system. The trials will determine 1) feasibility and acceptability of screening for social risks, identifying social needs and implementing referral service linkages (e.g., addressing transportation and housing needs, food insecurity, etc.) within the context of a healthcare visit, and 2) preliminary signals of the intervention’s impact on both the social risk/need(s) and NIDDK disease outcomes. Preliminary data regarding intervention efficacy are not required. The proposed pilot and feasibility clinical trials should lay the foundation for larger clinical trials to integrate social care and medical care and improve health outcomes related to the prevention and/or treatment of diseases within the mission of NIDDK. It is expected that these pilot studies will begin to delineate promising practices for future equitable and effective “real world” implementation of social and medical care integration. The overarching goal of this FOA is to develop pragmatic approaches that can be used in health care settings to reduce health disparities in diseases within the mission of NIDDK and achieve health equity, especially among individuals from racial and ethnic minority groups, rural populations, sexual and gender minority groups, and other socioeconomically disadvantaged and medically underserved communities. Posted 2/13/2023. Expires 10/20/2023.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs), including the NIDDK, based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials. Posted 11/9/2020. Upcoming special application due dates: May 26, 2023; September 26, 2023. Expires 12/29/2023.

Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional) The SUITOR program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described in the RFA. Posted 12/2/2021. Expires 5/8/2025.

T32 AWARDS

T32: Medical Student Research Training Supplement The Medical Student Research Training (MSRT) program provides mentored support for medical students interested in taking a year off from their medical school studies to work in an academic research lab. This support is via a supplement to a training grant (T32) in the appropriate area of research. A list of currently funded T32 program locations with the Principal Investigator contact information is available. Providing the opportunity for students to interrupt their medical school studies for up to 12 months to pursue a research project should help them solidify their decisions to pursue a research career, focus their research interests, and provide a background for future training and career development programs once they have completed their medical training. Posted 10/18/2021. Application Due Date(s) – April 18, 2023; January 18,2024; and April 18, 2024

COOPERATIVE AGREEMENT AWARDS (U series)

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (observational studies) – This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Posted 12/23/2020. Standard due dates. Expires 1/08/2024.

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement(clinical trials) – This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Posted 12/23/2020. Standard due dates. 1/08/2024.

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements  NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The activities required in the U34 will depend on the type of study (e.g., epidemiologic study, drug/device/biologics trial, behavior intervention). Because the purpose of the U34 is primarily for the conduct of administrative tasks needed to prepare for participant recruitment, activities involving human subjects will generally not be conducted during the U34 phase; however, brief activities involving interactions with individuals similar to those expected to participate in the full study during the U01 award may be allowed in order to aid in development of study procedures or operations (e.g., assessing usability of a form, device calibration, workflow optimization). As noted above, the U34 period may also include stakeholder engagement activities. The U34 is designed to: 1) permit early peer review of the rationale for the proposed clinical study; 2) permit assessment of the design and protocol of the proposed study; 3) provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Posted 12/23/2020. Upcoming special application due dates: June 8, 2023; February 15, 2024. Upcoming LOI due dates: May 8, 2023; January 15, 2024. Expires 2/16/2024.

OTHER AWARDS

Innovative Science Accelerator Program (ISAC) The ISAC Award provides seed funding for exceptionally innovative, disruptive (high-risk/high-reward) research relevant to Kidney-Urologic-Hematologic communities that has the potential to lead to groundbreaking or paradigm-shifting results that will change the field. ISAC awards are NOT Pilot & Feasibility projects for the generation of more preliminary data for traditional NIH applications (e.g., R01). Three-page applications are accepted on a rolling basis and reviewed three times a year. Investigators may request up to $100,000 (direct + indirect costs) total costs for one year. Standard application due dates: April 15, Aug 15, Dec 15.

NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) The NIDDK Catalyst Award is designed to complement NIDDK’s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK’s Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Posted 6/15/2023. Expires 9/29/2023.

Notice of Special Interest (NOSI): Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional) The mission of the NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH is committed to supporting research that will increase scientific understanding of the health and well-being of various population and subpopulation groups and that will help to establish the effectiveness of evidence-based health interventions and services for individuals within these groups. NIH places high priority on research with populations that have distinct health risk profiles and who have also received insufficient attention from the scientific research enterprise. To this end, this Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations or SGM-relevant research questions. SGM populations include, but are not limited to, those populations described in NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are encouraged to review the most recent annual Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI. More information about the SGM administrative supplements program and previously awarded research projects can be found on the SGMRO website. Posted 12/2/2021. Expires 2/1/2024.

HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery The purpose of this Notice of Special Interest (NOSI) is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to improve the translational application of animal models and/or outcome measures for the development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This NOSI is not specific for any one or group of pain conditions. Projects focused on acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region, pain co-occuring with substance use disorders, and other conditions will be considered. In addition to replication and validation of more commonly used translational animal models of pain, the development of animal models of pain for understudied pain conditions, age groups or less developed models is also encouraged. Posted 7/14/2022. Expires 6/25/2025.

NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed) The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository’s website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability. Posted 6/29/2022. Expires 6/27/2025.

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed) The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) whose research is supported by specific types of research grants that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting, mentoring, and supporting high school, undergraduate and graduate/clinical students, postbaccalaureate and post Masters individuals, postdoctoral researchers (including health professionals), and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to support PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. The activities proposed in the supplement application must fall within the scope of the parent grant, and simultaneously advance the objectives of the parent grant and support the research training and professional development of the supplement candidate. Posted 6/29/2023. Expires 5/8/2026.

NIH Loan Repayment Plan (LRPs):

The NIH Loan Repayment Programs (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The escalating costs of advanced education and training in medicine and clinical specialties are forcing some scientists to abandon their research careers for higher-paying private industry or private practice careers. The LRPs counteract that financial pressure by repaying up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research. Since tomorrow’s medical breakthroughs will be made by investigators starting in their research careers today, the LRPs represent an important investment by NIH in the future of health discovery and the wellbeing of the Nation.

From the National Institute on Aging:

Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. Posted 8/23/2021. Standard due dates. Expires 9/8/2023.

Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. Posted 7/7/2022. Expires 9/26/2025.

From other NIH institutes:

• Notice of Intent to Publish a Funding Opportunity Announcement for Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional)  The ComPASS Program is intended to make greater advances in promoting health and preventing disease among disproportionately impacted populations. ComPASS aims to be catalytic and cross-cutting in its integration of multisectoral partnerships, comprised of community organizations; local, state, Tribal, and federal governments; academic institutions and research organizations; and the private sector to address structural inequities that enable health disparities to persist. The program is transformative in its focus on structural health equity interventions given the evidenced impact of structural inequities on health outcomes. The ComPASS Program has two overall goals: 1) to catalyze, develop, and rigorously assess community-led, health equity structural interventions that leverage multisectoral partnerships to advance health equity; and 2) to develop a new health equity research model for community-led, multisectoral structural intervention research across NIH and other federal agencies.
• Notice of Intent to Publish a Funding Opportunity Announcement for Human Virome Project: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) The new funding opportunity will support cooperative agreement awards on tool and technology development as part of the HVP consortium. The goal of this initiative is to support the development of tools, models, and methods to address the technological and methodological challenges that are currently hindering robust interrogation into the constituents and functionality of the human virome. Current challenges include the heterogeneity of virome elements and the lack of universal viral molecular markers (analogous to bacterial 16S rRNA domains), sequencing errors that may lead to the false identification of viruses or variants, lack of standard references, difficulties working with low biomass samples, host and environmental DNA contamination, and inadequate bioinformatic tools for virome analysis.
• Notice of Intent to Publish a Funding Opportunity for the NIH Common Fund Human Virome Program: Characterization of functional interactions between viruses and human and microbial hosts (U01 Clinical Trial Not Allowed) The new funding opportunity will support HVP Functional Interaction Studies grants to join the HVP consortium. The goal of this initiative is to study interactions between the virome, human host, and microbiota and their functional implications on health and disease. The selected HVP Functional Interaction Studies projects will work collaboratively with each other and other components of the HVP consortium to develop and implement improved virome functional studies. Funding for the HVP will come from the NIH Common Fund, which supports cross-cutting programs expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and high-risk approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress.
• Notice of Intent to Publish a Funding Opportunity for the NIH Common Fund Human Virome Program: Consortium Organization and Data Collaboration Center (CODCC) for the Human Virome Project (HVP) (U24 Clinical Trial Not Allowed) The new funding opportunity will support the HVP CODCC to serve as an organizational hub to provide support for administrative activities, promotion of research protocols and tool development, and assist data and biospecimen collection and harmonization. The CODCC will create and maintain a program data portal that will be an interactive dashboard and repository with visualization and search capabilities. The data portal will also serve as the access point for the Human Virome Catalog, a key resource that will be generated by the CODCC from the samples and datasets generated by the HVP consortium, as well as other external datasets that might be available.
• Notice of Intent to Publish a Funding Opportunity for the NIH Common Fund Human Virome Program: Characterize the Human Virome in Longitudinal, Diverse Cohorts Across the Lifespan (U54 Clinical Trial Not Allowed) The new funding opportunity will support Virome Characterization Centers (VCCs) to join the HVP consortium. The goal of this initiative is to characterize the human virome and its dynamics by utilizing longitudinal, diverse human cohorts. This initiative aims to identify and characterize the viruses that comprise the human virome and provide an accurate estimate of its richness and complexity. At least six anatomic sites will be assessed by the HVP and include the blood; respiratory, gastrointestinal, and urogenital tracts (including urine/stool); oral cavity; central nervous system (CNS); skin. Other components, such as breast milk and tears, may also be examined. Responsive projects must aim to assess at least two or more of these anatomical sites, and the final coverage of all priority sites will be ensured programmatically before funding of awards.
• Notice of Special Interest (NOSI): Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional) The mission of the NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH is committed to supporting research that will increase scientific understanding of the health and well-being of various population and subpopulation groups and that will help to establish the effectiveness of evidence-based health interventions and services for individuals within these groups. NIH places high priority on research with populations that have distinct health risk profiles and who have also received insufficient attention from the scientific research enterprise. To this end, this Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations or SGM-relevant research questions. SGM populations include, but are not limited to, those populations described in NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are encouraged to review the most recent annual Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI. More information about the SGM administrative supplements program and previously awarded research projects can be found on the SGMRO website. Posted 12/2/2021. Expires 2/1/2024.
• Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional) Agency for HealthCare Research and Quality. The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Posted 2/9/2021. Standard due dates. Expires: 7/18/2024.
• Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00). The purpose of this program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH’s Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. Two awards are available: (1) K99/R00 Independent Clinical Trial Not Allowed; and (2) K99/R00 – Independent Clinical Trial Required. Posted 8/17/2021. Standard due dates. Expires 9/8/2024.
• Large Research Projects for Prevention of Healthcare-Associated Infections (R01) This Funding Opportunity Announcement (FOA) invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). Posted 7/7/2021. Standard due dates. Expires 5/27/2025.

*Follow the links to specific funding opportunities for more detailed information regarding deadlines and requirements. The deadlines for some of the following opportunities may have passed but have been identified as reoccurring opportunities.

Albert Einstein College of Medicine – Institute for Clinical & Translational Research (ICTR) Funding

• Catalytic Seed Grants
  • We invite applications from faculty members seeking seed funding to provide data for the development of extramural grant applications. Awards of up to $5,000 will be provided to investigators who will acquire new data to generate proposals for additional funding. Funds must be used for projects that will use ICTR Cores and Resources. Applications must be planned in consultation with the director(s) of the core or resource, who will help develop and approve the requested budget. Funds may not be used to purchase equipment or for salary support. Projects supported under this program must be clinical or translational in design or implementation. Priority for funding will be given to the current ICTR focus areas: (1) Pediatric determinants of adult health, (2) Experimental therapeutics, (3) Patient-centered outcomes research utilizing Montefiore Health System data.

Columbia University – Irving Institute for Clinical & Translational Research (IICTR) Funding

• Collaborative and Multidisciplinary Pilot Research (CaMPR) General and Integrating Special Populations (ISP) Pilot Award
  • The CaMPR and CaMPR-ISP program focuses on the innovative assembly of new teams to gather preliminary data to address unresolved clinical, translational and public health problems with novel approaches informed by interdisciplinary and multidisciplinary collaboration. Projects that use a community-engaged approach to research are encouraged (CECR).
• Community-Based Participatory Research Scholars and Awards Program
  • The Community Based Participatory Research Scholars and Awards Program is an innovative training and pilot funding opportunity for Columbia University faculty and administrators of not-for-profit organizations serving Upper Manhattan and The Bronx. The CBPR Program is designed to foster community-engaged research by giving participants structured training and practical experience in CBPR methodology. Up to five academic-community dyads are selected for the course. Academic-community co-instructors teach the CBPR course to model the partnership process. Upon completion of the training course, dyads are eligible to apply for a one-year CBPR pilot award of $30,000.

Duke University –Clinical & Translational Science Institute (CTSI) Funding

• Duke/NCCU Collaborative Translational Research Awards
  • This pilot program is designed to facilitate novel clinical, population, and translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and a high translational potential with a clear path for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practice or other channels.
• Duke/NC State Translational Research Agreement
  • This pilot program is designed to facilitate novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and high translational potential with a clear path for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practices, or other channels.
• Duke CTSI Special Populations Pilot
  • The purpose of the Special Populations Pilot program is to facilitate novel clinical and translational research that promotes health equity for groups who have traditionally been under-represented in health research or excluded altogether. Projects must have strong potential to inform subsequent grant applications for external funding. Pilot awards will be $25,000 (direct costs only); applications that include a strong community stakeholder-academic partnered approach will be eligible for an additional $10,000 for a total of $35,000 in pilot funding for a team that includes a strong community stakeholder-academic partnered approach. (see Community-Engaged Approaches below). Proposals from early stage and new investigators and proposals with collaborations across Duke Departments or Schools are highly encouraged.
• CTSI Translational Accelerator Research Funding Agreement
  • The Duke CTSI Translational Accelerator Research Funding Agreement provides up to $125,000 (direct costs only) to support novel translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and high translational potential for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practice, or other channels.
• CTSI Population Health Improvement Awards Program
  • This Awards program aims to engage community and academic partners in collaborative research that promotes novel ideas to improve community and population health. Duke CTSI, home of the National Institutes of Health’s Clinical and Translational Science Award at Duke, will provide approximately $100,000 annually to support pilot awards that can be used to either a) develop new community-research partnerships or b) foment already existing community and research partnerships that aim to develop and test effective solutions to improve community and population health. These partnerships and innovations can originate from community stakeholders or from Duke research partners but they must involve both community and research collaborators.
• Duke CTSI Multidisciplinary Vision Program (MVP) Award 
  • The Duke CTSI Multidisciplinary Vision Program (MVP) Award provides funding up to $110,000 per award to support novel clinical translational research focused on improving health and healthy equity. Duke CTSI supports clinical translational research endeavors under the following domains: Methods/Processes, Collaboration/Engagement, Informatics, Integration Across the Lifespan, and Workforce Development. Proposals from teams of investigators from different disciplines are encouraged. Collaborations that bring together ideas, theories, methods and approaches from disparate scientific disciplines are particularly encouraged.

Mayo Clinic – Center for Clinical and Translational Science (CCATS) Funding

• Community Health: Assessment and Improvement Measures Program Partnership Development Award
  • The goal of the Mayo Clinic Center for Clinical and Translational Science (CCaTS) CHAMP Partnership Development Award is to support community-academic partnership activities needed for research engagement. The CHAMP Partnership Development Award supports one-year projects in which community partners or research teams work in tandem with CCaTS‘ Community Engagement in Research Program to help with partnership identification, development, project planning or a combination thereof.

Stanford University – Stanford Center for Clinical and Translational Research and Education (Spectrum) Funding

• Spectrum Community Engagement Pilot Grant 
  • Spectrum offers pilot grants for accelerating clinical and translational research in biomedical and health-related areas. The Spectrum Pilot Program has two major goals: to stimulate innovative clinical and translational research and to encourage collaborative, transdisciplinary work. The primary expectation is that these early-stage translational projects will lead to additional research, external support, information dissemination, and most importantly, will develop into longer-term, comprehensive projects. The projects must have a community engagement component that highlights ways to incorporate community members’ input in the design and implementation of the proposed project.

University of Alabama at Birmingham – Center for Clinical & Translational Science (CCTS) Funding

• CCTS Interdisciplinary Network Pilot Program
  • Through the CCTS Pilot Program, we seek to (a) ameliorate disparities in diseases that disproportionately affect minority and special populations across the CCTS Partner Network and (b) develop the future translational research workforce by fostering collaboration, team science and innovative discovery. Special consideration will be given to projects that include community-engaged research.
• Voucher Programs
  • The mission of the Center for Clinical and Translational Science (CCTS) is to address disparities and diseases disproportionately represented within the Deep South as we accelerate discovery to improve human health. Vouchers help overcome barriers to conducting mission-aligned investigation by connecting investigators with clinical, translational or community-based research goals to the facilities, resources and expertise they need. Vouchers are intended for active research efforts that are ready to use these resources immediately.

University of California San Francisco – Clinical & Translational Science Institute (CTSI) Funding

• Pilot for Research on Racism Impacting Black People
  • The UCSF Office of Research has committed to the goal of anti-racism and racial equity in research. As one action for this initiative, the Office of Research has convened campus partners to create an anti-racism research pilot grant program. Funding for this initiative is provided by the Clinical and Translational Science Institute (CTSI), Academic Senate, School of Medicine’s Research Evaluation and Allocation Committee (REAC), and the Research Development Office. Community-academic partnerships are encouraged and may include local, county, or state governments, police departments, court systems, and/or high-impact nonprofits or community-based organizations.
• Team Science Grant
  • The goal of this award is to spark innovation by stimulating new collaborations between researchers from diverse fields and/or between researchers and community partners. For the purposes of this funding opportunity, ‘Team Science’ is broadly defined, including multiple scientific disciplines, and encouraging but not requiring non-traditional investigators from community-based settings as co-investigators. Non-traditional co-I’s may include stakeholders who are expected in the longer term to benefit from research outcomes, such as representatives of patient and community groups, healthcare organizations, or policy makers. This award will provide funding to facilitate cross-disciplinary research projects concerning any subject area in biomedical, population health, and health services research.

University of Michigan – Michigan Institute for Clinical and Health Research (MICHR) Funding

• MICHR Clinical and Translational Science Pilot Award
  • The MICHR Clinical and Translational Science Pilot Award aims to support new and innovative research projects relevant to clinical & translational science (CTS). CTS is a field of investigation focused on understanding a scientific or operational principle that underlies a step of the translational process, with the goal of developing generalizable principles to accelerate translational research. We encourage applications that propose addressing a common cause of inefficiency or failure in research projects at any stage of translation, with the goal of producing foundational knowledge that will ultimately improve health.

University of Pennsylvania – Institute for Translational Medicine and Therapeutics (ITMAT) Funding

• CEAR CTSA Pilot Grant Program
  • The Community Engagement and Research (CEAR) core of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania is sponsoring a pilot grant program to fund research with public and community health relevance. The CEAR Core is seeking proposals that foster community-based research, especially studies that use a participatory framework. This includes research conducted in community settings or using a participatory research framework that actively involves community stakeholders in the conceptualization, design, implementation, and/or evaluation. “Community” is defined broadly to include populations in neighborhoods and organizations, including health care settings.

University of Pittsburgh – Clinical and Translational Science Institute (CTSI) Funding

• CRISP: CTSI’s Research Initiative for Special Populations
  • CRISP offers campus investigators up to $25,000 in funding to support research initiatives that work with groups that are frequently underrepresented in research. Applications that demonstrate a meaningful partnership with a community organization may be eligible for an additional $5,000 in bonus funding (see the bonus round section below for additional information).
• The Pitt Innovation Challenge
  • The Pitt Innovation Challenge (PInCh®) is seeking your bold solution to a challenging health problem. We encourage proposals from any discipline and on any topic that impacts health. Ideas can span the spectrum of health and healthcare, including disease prevention, diagnostics, treatments, interventions, predictive solutions, patient care, provider and patient tools, and community programs. We encourage projects that create new connections within the academic community, and among universities and community organizations.
• Wordout Community Research Dissemination Challenge
  • The Community PARTners Core at the Clinical and Translational Science Institute (CTSI) is now accepting applications for the WORDOUT Community Research Dissemination Challenge. WORDOUT is an exciting program that matches researchers from the University of Pittsburgh with local community organizations to help get the “word out” about the latest in research dissemination. We are once again matching community organizations with researchers to work together to both share lived experiences of folks in the community, and think about creative ways to disseminate research.

University of Wisconsin-Madison – Institute for Clinical & Translational Research (ICTR) Funding

• Stakeholder & Patient Engaged Research (SPER) Pilot Award
  • The goal of this Stakeholder and Patient Engaged Research (SPER) RFA is to provide support for activities that will strengthen a competitive application for external funding for research requiring strong stakeholder engagement as a foundation for a successful application. This includes but is not limited to PCOR. New or previously unsuccessful applicants to PCOR funders are encouraged to apply. (Deadline passed)
• Clinical & Community Outcomes Research (CCOR) Pilot Award
  • The goal of the Clinical & Community Outcomes Research (CCOR) Pilot Award is to support excellent, community-partnered health research that solves problems translating knowledge into improvements in clinical practice, community programs and health policy. This pilot award may also support the development of interventions that require individual, organizational, or system behavior change. (Deadline passed)
• Collaborative Health Equity Research (CHER) Pilot Award
  • To support new community-engaged research projects focused on health disparities/inequities wherein the PI is an early stage investigator, e.g., assistant professor, and a senior co-investigator is engaged to ensure a mentored experience and to connect the research team with relevant stakeholders. (Deadline passed)
• Dissemination & Implementation Research (D&I) Pilot Award
  • To support research that addresses how to best ensure that evidence-based strategies/interventions/programs are effectively delivered in clinical and community health practice settings and impact policy. The successful grantee will use the results of this award to seek further extramural peer reviewed funding for the research. (Deadline passed)

Washington University in St. Louis – Institute of Clinical & Translational Sciences (ICTS) Funding

• Clinical and Translational Research Funding Program (CTRFP)
  • As an internal grant funding program of the ICTS, the Clinical and Translational Research Funding Program (CTRFP) awards projects that promote the translation of scientific discoveries into improvement in human health. Awards will be considered for Community-Engaged Research Projects that involve established partnerships with communities and/or stakeholders whose health and well-being and/or service provision could be most impacted by the research.
• Partnership Development & Sustainability Support (PDSS)
  • Through our Center for Community Health Partnership & Research, the ICTS launched the PDSS to provide ICTS investigators and their community partner(s) with up to $10,000 over a 9-month period to develop the trust, infrastructure, capacity, and skills needed to support future collaborative grant opportunities. The PDSS is open to new partnerships in development, as well as existing partnerships.

Other Funding Announcements

Innovative Science Accelerator Program (ISAC) The ISAC Award provides seed funding for exceptionally innovative, disruptive (high-risk/high-reward) research relevant to Kidney-Urologic-Hematologic communities that has the potential to lead to groundbreaking or paradigm-shifting results that will change the field. ISAC awards are NOT Pilot & Feasibility projects for the generation of more preliminary data for traditional NIH applications (e.g., R01). Three-page applications are accepted on a rolling basis and reviewed three times a year. Investigators may request up to $100,000 (direct + indirect costs) total costs for one year. Standard application due dates: April 15, Aug 15, Dec 15.

Ruth L. Kirschstein National Research Service Award Institutional Research Training Awards NRSA awards support the training of biomedical, behavioral, and clinical researchers through individual pre- and postdoctoral fellowships, and institutional research training grants. Search for funding opportunities by career stage HERE. NIH now provides childcare cost support to full-time predoctoral and postdoctoral trainees appointed on NRSA institutional research training awards. The NRSA childcare costs apply to each full-time predoctoral or postdoctoral NIH-NRSA-supported institutional research training award appointment. Each trainee is eligible to receive $2,500 per budget period for childcare costs provided by a licensed childcare provider.